In Pivotal Phase III Studies, Merck’s Investigational Medicine Boceprevir Helped Majority of Patients With Chronic …

Published August 4, 2010

In Pivotal Phase III Studies, Merck’s Investigational Medicine Boceprevir Helped Majority of Patients with Chronic …
WHITEHOUSE STATION, N.J.—-Merck today reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the …
Read more on Business Wire via Yahoo! Finance

A fatal crash, remorse, another crash
After causing the chain-reaction car crash that killed her daughter in 2006, Anthony Klecker apologized to Catherine Casey in court for his drunken recklessness.
Read more on Pioneer Press

Data From Meta-Analysis Show Victoza(R) Achieved Improved Blood Sugar Control in African-Americans With Type 2 Diabetes
ORLANDO, FL–(Marketwire – August 4, 2010) – Novo Nordisk ( NYSE : NVO ) presented results today demonstrating that once-daily Victoza ® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes …
Read more on Marketwire